Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

MT Newswires Live03-23 21:12

Health care stocks were flat to higher pre-bell Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 1.5%.

Apogee Therapeutics (APGE) stock was up more than 16% after the company said 52-week maintenance data from Part A of its phase two trial of zumilokibart in patients with moderate-to-severe atopic dermatitis demonstrated durable maintenance response and "deepening" response for lesional and itch endpoints.

Bausch + Lomb (BLCO) shares were up more than 5% after the company said the US clinical trial of its Elios system for the treatment of elevated intraocular pressure in patients with open angle glaucoma showed statistically significant intraocular pressure reduction after 24 months.

Ionis Pharmaceuticals (IONS) shares were up more than 1% after the company said the US Food and Drug Administration granted priority review designation for its new drug application for zilganersen as a potential treatment for Alexander disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621706787?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621706787","market":"fut","top_or_hot":-1,"title":"Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday","media":"MT Newswires Live","content":"<html><body><p> Health care stocks were flat to higher pre-bell Monday, with the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 1.5%.</p><p><a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> (APGE) stock was up more than 16% after the company said 52-week maintenance data from Part A of its phase two trial of zumilokibart in patients with moderate-to-severe atopic dermatitis demonstrated durable maintenance response and \"deepening\" response for lesional and itch endpoints.</p><p>Bausch + Lomb (BLCO) shares were up more than 5% after the company said the US clinical trial of its Elios system for the treatment of elevated intraocular pressure in patients with open angle glaucoma showed statistically significant intraocular pressure reduction after 24 months.</p><p>Ionis Pharmaceuticals (IONS) shares were up more than 1% after the company said the US Food and Drug Administration granted priority review designation for its new drug application for zilganersen as a potential treatment for Alexander disease.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Health Care Stocks Flat to Higher Pre-Bell Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-23 21:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Health care stocks were flat to higher pre-bell Monday, with the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 1.5%.</p><p><a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> (APGE) stock was up more than 16% after the company said 52-week maintenance data from Part A of its phase two trial of zumilokibart in patients with moderate-to-severe atopic dermatitis demonstrated durable maintenance response and \"deepening\" response for lesional and itch endpoints.</p><p>Bausch + Lomb (BLCO) shares were up more than 5% after the company said the US clinical trial of its Elios system for the treatment of elevated intraocular pressure in patients with open angle glaucoma showed statistically significant intraocular pressure reduction after 24 months.</p><p>Ionis Pharmaceuticals (IONS) shares were up more than 1% after the company said the US Food and Drug Administration granted priority review designation for its new drug application for zilganersen as a potential treatment for Alexander disease.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IONS","symbol_name":"Ionis Pharmaceuticals, Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2621706787","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621706787","pubTimestamp":1774271557,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Health care stocks were flat to higher pre-bell Monday, with the iShares Biotechnology ETF  inactive and the State Street Health Care Select Sector SPDR ETF  up 1.5%.Apogee Therapeutics  stock was up more than 16% after the company said 52-week maintenance data from Part A of its phase two trial of zumilokibart in patients with moderate-to-severe atopic dermatitis demonstrated durable maintenance response and \"deepening\" response for lesional and itch endpoints.Bausch + Lomb  shares were up more than 5% after the company said the US clinical trial of its Elios system for the treatment of elevated intraocular pressure in patients with open angle glaucoma showed statistically significant intraocular pressure reduction after 24 months.Ionis Pharmaceuticals  shares were up more than 1% after the company said the US Food and Drug Administration granted priority review designation for its new drug application for zilganersen as a potential treatment for Alexander disease.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IONS":"Ionis Pharmaceuticals, Inc","BK4588":"碎股","BLCO":"博士伦","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品","APGE":"Apogee Therapeutics","XLV":"健康照护类股ETF-SPDR","IBB":"生物科技指数ETF-iShares Nasdaq","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4581":"高盛持仓","BK4139":"生物科技","XBI":"SPDR S&P Biotech ETF","LABU":"三倍做多标普生物-Direxion"},"translate_title":"行业更新：医疗保健股周一盘前持平至走高","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XLV":1.5,"BLCO":1,"LABU":0.6,"XBI":0.6,"IONS":1,"IBB":1,"APGE":1},"content_text":"Health care stocks were flat to higher pre-bell Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 1.5%.Apogee Therapeutics (APGE) stock was up more than 16% after the company said 52-week maintenance data from Part A of its phase two trial of zumilokibart in patients with moderate-to-severe atopic dermatitis demonstrated durable maintenance response and \"deepening\" response for lesional and itch endpoints.Bausch + Lomb (BLCO) shares were up more than 5% after the company said the US clinical trial of its Elios system for the treatment of elevated intraocular pressure in patients with open angle glaucoma showed statistically significant intraocular pressure reduction after 24 months.Ionis Pharmaceuticals (IONS) shares were up more than 1% after the company said the US Food and Drug Administration granted priority review designation for its new drug application for zilganersen as a potential treatment for Alexander disease.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621706787","isCrawlerRequest":true}